Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023 -November 10, 2023 at 08:58 am EST

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due...

Related Keywords

United States ,Boston ,Massachusetts ,Americans ,Kitty Yale ,Stephena Harrison ,Sarah Oconnell ,Austin Murtagh ,Exchange Commission ,Linkedin ,Akero Therapeutics Inc ,Twitter ,Nasdaq ,Pinnacle Clinical Research ,American Association ,Liver Disease ,Liver Meeting ,Presentation Title ,Decompensated Cirrhosis ,Medical Director ,Breaker Abstract Number ,Late Breaking Abstract ,Late Breaking Parallel ,General Session Ballroom ,Combination With ,Placebo Controlled Study ,Late Breaking ,South San ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,